Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 16 entries
Sorted by: Best Match Show Resources per page
Presepsin (scd14) as a marker of serious bacterial infections in chemotherapy induced severe neutropenia.

Iranian journal of pediatrics

Olad E, Sedighi I, Mehrvar A, Tashvighi M, Fallahazad V, Hedayatiasl A, Esfahani H.
PMID: 26019777
Iran J Pediatr. 2014 Dec;24(6):715-22. Epub 2014 Nov 28.

OBJECTIVE: Timely detection of serious bacterial infections or prediction of sepsis and death is of paramount importance in neutropenic patients especially in oncology settings. The aim of this study was to determine a rapid and secure predictor of sepsis...

Cite
Olad E, Sedighi I, Mehrvar A, et al. Presepsin (scd14) as a marker of serious bacterial infections in chemotherapy induced severe neutropenia. Iran J Pediatr. 2014;24(6):715-22
Olad, E., Sedighi, I., Mehrvar, A., Tashvighi, M., Fallahazad, V., Hedayatiasl, A., & Esfahani, H. (2014). Presepsin (scd14) as a marker of serious bacterial infections in chemotherapy induced severe neutropenia. Iranian journal of pediatrics, 24(6), 715-22.
Olad, Elham, et al. "Presepsin (scd14) as a marker of serious bacterial infections in chemotherapy induced severe neutropenia." Iranian journal of pediatrics vol. 24,6 (2014): 715-22.
Olad E, Sedighi I, Mehrvar A, Tashvighi M, Fallahazad V, Hedayatiasl A, Esfahani H. Presepsin (scd14) as a marker of serious bacterial infections in chemotherapy induced severe neutropenia. Iran J Pediatr. 2014 Dec;24(6):715-22. Epub 2014 Nov 28. PMID: 26019777; PMCID: PMC4442833.
Copy Download .nbib Format: NLM
Successful treatment of progressive macular hypomelanosis.

Dermatology reports

Leonard N, Krueger S, Rashighi M.
PMID: 33408831
Dermatol Reports. 2020 Oct 22;12(2):8509. doi: 10.4081/dr.2020.8509. eCollection 2020 Sep 23.

Progressive Macular Hypomelanosis (PMH) is a common but often misdiagnosed disorder of acquired hypopigmentation. An adolescent female presented with irregular, hypopigmented patches ultimately diagnosed as PMH. Complete repigmentation was achieved with narrowband UVB phototherapy, benzoyl peroxide wash, and clindamycin...

Cite
Leonard N, Krueger S, Rashighi M. Successful treatment of progressive macular hypomelanosis. Dermatol Reports. 2020;12(2):8509doi: 10.4081/dr.2020.8509.
Leonard, N., Krueger, S., & Rashighi, M. (2020). Successful treatment of progressive macular hypomelanosis. Dermatology reports, 12(2), 8509. https://doi.org/10.4081/dr.2020.8509
Leonard, Nicholas, et al. "Successful treatment of progressive macular hypomelanosis." Dermatology reports vol. 12,2 (2020): 8509. doi: https://doi.org/10.4081/dr.2020.8509
Leonard N, Krueger S, Rashighi M. Successful treatment of progressive macular hypomelanosis. Dermatol Reports. 2020 Oct 22;12(2):8509. doi: 10.4081/dr.2020.8509. eCollection 2020 Sep 23. PMID: 33408831; PMCID: PMC7772758.
Copy Download .nbib Format: NLM
Mesenchymal Stem Cells and Co-stimulation Blockade Enhance Bone Marrow Engraftment and Induce Immunological Tolerance.

International journal of organ transplantation medicine

Rajeshkumar B, Agrawal P, Rashighi M, Saidi RF.
PMID: 26082829
Int J Organ Transplant Med. 2015;6(2):55-60.

BACKGROUND: Organ transplantation currently requires long-term immunosuppression. This is associated with multiple complications including infection, malignancy and other toxicities. Immunologic tolerance is considered the optimal solution to these limitations.OBJECTIVE: To develop a simple and non-toxic regimen to induce mixed...

Cite
Rajeshkumar B, Agrawal P, Rashighi M, et al. Mesenchymal Stem Cells and Co-stimulation Blockade Enhance Bone Marrow Engraftment and Induce Immunological Tolerance. Int J Organ Transplant Med. 2015;6(2):55-60
Rajeshkumar, B., Agrawal, P., Rashighi, M., & Saidi, R. F. (2015). Mesenchymal Stem Cells and Co-stimulation Blockade Enhance Bone Marrow Engraftment and Induce Immunological Tolerance. International journal of organ transplantation medicine, 6(2), 55-60.
Rajeshkumar, B, et al. "Mesenchymal Stem Cells and Co-stimulation Blockade Enhance Bone Marrow Engraftment and Induce Immunological Tolerance." International journal of organ transplantation medicine vol. 6,2 (2015): 55-60.
Rajeshkumar B, Agrawal P, Rashighi M, Saidi RF. Mesenchymal Stem Cells and Co-stimulation Blockade Enhance Bone Marrow Engraftment and Induce Immunological Tolerance. Int J Organ Transplant Med. 2015;6(2):55-60. PMID: 26082829; PMCID: PMC4464279.
Copy Download .nbib Format: NLM
Response to the influence of teledermatology on health care access and equity.

Journal of the American Academy of Dermatology

Franciosi EB, Tan AJ, Kassamali B, O'Connor DM, Rashighi M, LaChance A.
PMID: 33359783
J Am Acad Dermatol. 2021 Apr;84(4):e221-e222. doi: 10.1016/j.jaad.2020.12.037. Epub 2020 Dec 24.

No abstract available.

Cite
Franciosi EB, Tan AJ, Kassamali B, et al. Response to the influence of teledermatology on health care access and equity. J Am Acad Dermatol. 2020;84(4):e221-e222doi: 10.1016/j.jaad.2020.12.037.
Franciosi, E. B., Tan, A. J., Kassamali, B., O'Connor, D. M., Rashighi, M., & LaChance, A. (2021). Response to the influence of teledermatology on health care access and equity. Journal of the American Academy of Dermatology, 84(4), e221-e222. https://doi.org/10.1016/j.jaad.2020.12.037
Franciosi, Ellen B, et al. "Response to the influence of teledermatology on health care access and equity." Journal of the American Academy of Dermatology vol. 84,4 (2021): e221-e222. doi: https://doi.org/10.1016/j.jaad.2020.12.037
Franciosi EB, Tan AJ, Kassamali B, O'Connor DM, Rashighi M, LaChance A. Response to the influence of teledermatology on health care access and equity. J Am Acad Dermatol. 2021 Apr;84(4):e221-e222. doi: 10.1016/j.jaad.2020.12.037. Epub 2020 Dec 24. PMID: 33359783.
Copy Download .nbib Format: NLM
Treatment and outcomes of pediatric patients with cancer and COVID-19 at MAHAK pediatric cancer treatment and research center, Tehran, Iran.

Seminars in oncology

Mehrvar A, Qaddoumi I, Tashvighi M, Naderi A, Mousakhani H, Alasvand R, Shekarchi B, Afsar N, Nourian M, Mehrvar N.
PMID: 34625294
Semin Oncol. 2021 Sep 08; doi: 10.1053/j.seminoncol.2021.09.003. Epub 2021 Sep 08.

The COVID-19 pandemic has been particularly devastating for Iran. Children with cancer are generally immunosuppressed and especially vulnerable to SARS-CoV-2 infections. We report the treatment and outcomes of pediatric oncology patients with COVID-19 at the MAHAK Pediatric Cancer Treatment...

Cite
Mehrvar A, Qaddoumi I, Tashvighi M, et al. Treatment and outcomes of pediatric patients with cancer and COVID-19 at MAHAK pediatric cancer treatment and research center, Tehran, Iran. Semin Oncol. 2021;doi: 10.1053/j.seminoncol.2021.09.003.
Mehrvar, A., Qaddoumi, I., Tashvighi, M., Naderi, A., Mousakhani, H., Alasvand, R., Shekarchi, B., Afsar, N., Nourian, M., & Mehrvar, N. (2021). Treatment and outcomes of pediatric patients with cancer and COVID-19 at MAHAK pediatric cancer treatment and research center, Tehran, Iran. Seminars in oncology, . https://doi.org/10.1053/j.seminoncol.2021.09.003
Mehrvar, Azim, et al. "Treatment and outcomes of pediatric patients with cancer and COVID-19 at MAHAK pediatric cancer treatment and research center, Tehran, Iran." Seminars in oncology vol. (2021). doi: https://doi.org/10.1053/j.seminoncol.2021.09.003
Mehrvar A, Qaddoumi I, Tashvighi M, Naderi A, Mousakhani H, Alasvand R, Shekarchi B, Afsar N, Nourian M, Mehrvar N. Treatment and outcomes of pediatric patients with cancer and COVID-19 at MAHAK pediatric cancer treatment and research center, Tehran, Iran. Semin Oncol. 2021 Sep 08; doi: 10.1053/j.seminoncol.2021.09.003. Epub 2021 Sep 08. PMID: 34625294; PMCID: PMC8424019.
Copy Download .nbib Format: NLM
Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo.

Annals of translational medicine

Rashighi M, Harris JE.
PMID: 26734651
Ann Transl Med. 2015 Dec;3(21):343. doi: 10.3978/j.issn.2305-5839.2015.11.36.

No abstract available.

Cite
Rashighi M, Harris JE. Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo. Ann Transl Med. 2015;3(21):343doi: 10.3978/j.issn.2305-5839.2015.11.36.
Rashighi, M., & Harris, J. E. (2015). Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo. Annals of translational medicine, 3(21), 343. https://doi.org/10.3978/j.issn.2305-5839.2015.11.36
Rashighi, Mehdi, and Harris, John E. "Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo." Annals of translational medicine vol. 3,21 (2015): 343. doi: https://doi.org/10.3978/j.issn.2305-5839.2015.11.36
Rashighi M, Harris JE. Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo. Ann Transl Med. 2015 Dec;3(21):343. doi: 10.3978/j.issn.2305-5839.2015.11.36. PMID: 26734651; PMCID: PMC4690998.
Copy Download .nbib Format: NLM
Identifying trends in patient characteristics and visit details during the transition to teledermatology: Experience at a single tertiary referral center.

Journal of the American Academy of Dermatology

Krueger S, Leonard N, Modest N, Flahive J, Guilarte-Walker Y, Rashighi M, LaChance AH.
PMID: 33253853
J Am Acad Dermatol. 2021 Dec;85(6):1592-1594. doi: 10.1016/j.jaad.2020.11.040. Epub 2020 Nov 27.

No abstract available.

Cite
Krueger S, Leonard N, Modest N, et al. Identifying trends in patient characteristics and visit details during the transition to teledermatology: Experience at a single tertiary referral center. J Am Acad Dermatol. 2020;85(6):1592-1594doi: 10.1016/j.jaad.2020.11.040.
Krueger, S., Leonard, N., Modest, N., Flahive, J., Guilarte-Walker, Y., Rashighi, M., & LaChance, A. H. (2021). Identifying trends in patient characteristics and visit details during the transition to teledermatology: Experience at a single tertiary referral center. Journal of the American Academy of Dermatology, 85(6), 1592-1594. https://doi.org/10.1016/j.jaad.2020.11.040
Krueger, Steven, et al. "Identifying trends in patient characteristics and visit details during the transition to teledermatology: Experience at a single tertiary referral center." Journal of the American Academy of Dermatology vol. 85,6 (2021): 1592-1594. doi: https://doi.org/10.1016/j.jaad.2020.11.040
Krueger S, Leonard N, Modest N, Flahive J, Guilarte-Walker Y, Rashighi M, LaChance AH. Identifying trends in patient characteristics and visit details during the transition to teledermatology: Experience at a single tertiary referral center. J Am Acad Dermatol. 2021 Dec;85(6):1592-1594. doi: 10.1016/j.jaad.2020.11.040. Epub 2020 Nov 27. PMID: 33253853.
Copy Download .nbib Format: NLM
Evaluation of Relationship Between Demographics and Dental Status in a Defined Group of Iranian Paediatric Patients Undergoing Cancer Therapy.

Journal of clinical and diagnostic research : JCDR

Mortazavi H, Tashvighi M, Azizian M, Khalighi HR, Sabour S, Movahhedian A, Baharvand M.
PMID: 26501019
J Clin Diagn Res. 2015 Sep;9(9):ZC80-3. doi: 10.7860/JCDR/2015/11976.6521. Epub 2015 Sep 01.

CONTEXT: Cancer is a major cause of death in children under 15 years of age.AIMS: This study aimed to evaluate relationship between demographics and dental status in a defined group of Iranian paediatric patients undergoing cancer therapy.SETTINGS AND DESIGN:...

Cite
Mortazavi H, Tashvighi M, Azizian M, et al. Evaluation of Relationship Between Demographics and Dental Status in a Defined Group of Iranian Paediatric Patients Undergoing Cancer Therapy. J Clin Diagn Res. 2015;9(9):ZC80-3doi: 10.7860/JCDR/2015/11976.6521.
Mortazavi, H., Tashvighi, M., Azizian, M., Khalighi, H. R., Sabour, S., Movahhedian, A., & Baharvand, M. (2015). Evaluation of Relationship Between Demographics and Dental Status in a Defined Group of Iranian Paediatric Patients Undergoing Cancer Therapy. Journal of clinical and diagnostic research : JCDR, 9(9), ZC80-3. https://doi.org/10.7860/JCDR/2015/11976.6521
Mortazavi, Hamed, et al. "Evaluation of Relationship Between Demographics and Dental Status in a Defined Group of Iranian Paediatric Patients Undergoing Cancer Therapy." Journal of clinical and diagnostic research : JCDR vol. 9,9 (2015): ZC80-3. doi: https://doi.org/10.7860/JCDR/2015/11976.6521
Mortazavi H, Tashvighi M, Azizian M, Khalighi HR, Sabour S, Movahhedian A, Baharvand M. Evaluation of Relationship Between Demographics and Dental Status in a Defined Group of Iranian Paediatric Patients Undergoing Cancer Therapy. J Clin Diagn Res. 2015 Sep;9(9):ZC80-3. doi: 10.7860/JCDR/2015/11976.6521. Epub 2015 Sep 01. PMID: 26501019; PMCID: PMC4606348.
Copy Download .nbib Format: NLM
The effect of adjuvant zinc therapy on recovery from pneumonia in hospitalized children: a double-blind randomized controlled trial.

Scientifica

Qasemzadeh MJ, Fathi M, Tashvighi M, Gharehbeglou M, Yadollah-Damavandi S, Parsa Y, Rahimi E.
PMID: 24955282
Scientifica (Cairo). 2014;2014:694193. doi: 10.1155/2014/694193. Epub 2014 May 12.

Objectives. Pneumonia is one of the common mortality causes in young children. Some studies have shown beneficial effect of zinc supplements on treatment of pneumonia. The present study aimed to investigate the effects of short courses of zinc administration...

Cite
Qasemzadeh MJ, Fathi M, Tashvighi M, et al. The effect of adjuvant zinc therapy on recovery from pneumonia in hospitalized children: a double-blind randomized controlled trial. Scientifica (Cairo). 2014;2014:694193doi: 10.1155/2014/694193.
Qasemzadeh, M. J., Fathi, M., Tashvighi, M., Gharehbeglou, M., Yadollah-Damavandi, S., Parsa, Y., & Rahimi, E. (2014). The effect of adjuvant zinc therapy on recovery from pneumonia in hospitalized children: a double-blind randomized controlled trial. Scientifica, 2014694193. https://doi.org/10.1155/2014/694193
Qasemzadeh, Mohammad Javad, et al. "The effect of adjuvant zinc therapy on recovery from pneumonia in hospitalized children: a double-blind randomized controlled trial." Scientifica vol. 2014 (2014): 694193. doi: https://doi.org/10.1155/2014/694193
Qasemzadeh MJ, Fathi M, Tashvighi M, Gharehbeglou M, Yadollah-Damavandi S, Parsa Y, Rahimi E. The effect of adjuvant zinc therapy on recovery from pneumonia in hospitalized children: a double-blind randomized controlled trial. Scientifica (Cairo). 2014;2014:694193. doi: 10.1155/2014/694193. Epub 2014 May 12. PMID: 24955282; PMCID: PMC4052786.
Copy Download .nbib Format: NLM
Treatment and outcomes of pediatric patients with cancer and COVID-19 at MAHAK pediatric cancer treatment and research center, Tehran, Iran.

Seminars in oncology

Mehrvar A, Qaddoumi I, Tashvighi M, Naderi A, Mousakhani H, Alasvand R, Shekarchi B, Afsar N, Nourian M, Mehrvar N.
PMID: 34625294
Semin Oncol. 2021 Aug-Dec;48(4):295-303. doi: 10.1053/j.seminoncol.2021.09.003. Epub 2021 Sep 08.

The COVID-19 pandemic has been particularly devastating for Iran. Children with cancer are generally immunosuppressed and especially vulnerable to SARS-CoV-2 infections. We report the treatment and outcomes of pediatric oncology patients with COVID-19 at the MAHAK Pediatric Cancer Treatment...

Cite
Mehrvar A, Qaddoumi I, Tashvighi M, et al. Treatment and outcomes of pediatric patients with cancer and COVID-19 at MAHAK pediatric cancer treatment and research center, Tehran, Iran. Semin Oncol. 2021;48(4):295-303doi: 10.1053/j.seminoncol.2021.09.003.
Mehrvar, A., Qaddoumi, I., Tashvighi, M., Naderi, A., Mousakhani, H., Alasvand, R., Shekarchi, B., Afsar, N., Nourian, M., & Mehrvar, N. (2021). Treatment and outcomes of pediatric patients with cancer and COVID-19 at MAHAK pediatric cancer treatment and research center, Tehran, Iran. Seminars in oncology, 48(4), 295-303. https://doi.org/10.1053/j.seminoncol.2021.09.003
Mehrvar, Azim, et al. "Treatment and outcomes of pediatric patients with cancer and COVID-19 at MAHAK pediatric cancer treatment and research center, Tehran, Iran." Seminars in oncology vol. 48,4 (2021): 295-303. doi: https://doi.org/10.1053/j.seminoncol.2021.09.003
Mehrvar A, Qaddoumi I, Tashvighi M, Naderi A, Mousakhani H, Alasvand R, Shekarchi B, Afsar N, Nourian M, Mehrvar N. Treatment and outcomes of pediatric patients with cancer and COVID-19 at MAHAK pediatric cancer treatment and research center, Tehran, Iran. Semin Oncol. 2021 Aug-Dec;48(4):295-303. doi: 10.1053/j.seminoncol.2021.09.003. Epub 2021 Sep 08. PMID: 34625294; PMCID: PMC8424019.
Copy Download .nbib Format: NLM
Identifying trends in patient characteristics and visit details during the transition to teledermatology: Experience at a single tertiary referral center.

Journal of the American Academy of Dermatology

Krueger S, Leonard N, Modest N, Flahive J, Guilarte-Walker Y, Rashighi M, LaChance AH.
PMID: 33253853
J Am Acad Dermatol. 2021 Dec;85(6):1592-1594. doi: 10.1016/j.jaad.2020.11.040. Epub 2020 Nov 27.

No abstract available.

Cite
Krueger S, Leonard N, Modest N, et al. Identifying trends in patient characteristics and visit details during the transition to teledermatology: Experience at a single tertiary referral center. J Am Acad Dermatol. 2020;85(6):1592-1594doi: 10.1016/j.jaad.2020.11.040.
Krueger, S., Leonard, N., Modest, N., Flahive, J., Guilarte-Walker, Y., Rashighi, M., & LaChance, A. H. (2021). Identifying trends in patient characteristics and visit details during the transition to teledermatology: Experience at a single tertiary referral center. Journal of the American Academy of Dermatology, 85(6), 1592-1594. https://doi.org/10.1016/j.jaad.2020.11.040
Krueger, Steven, et al. "Identifying trends in patient characteristics and visit details during the transition to teledermatology: Experience at a single tertiary referral center." Journal of the American Academy of Dermatology vol. 85,6 (2021): 1592-1594. doi: https://doi.org/10.1016/j.jaad.2020.11.040
Krueger S, Leonard N, Modest N, Flahive J, Guilarte-Walker Y, Rashighi M, LaChance AH. Identifying trends in patient characteristics and visit details during the transition to teledermatology: Experience at a single tertiary referral center. J Am Acad Dermatol. 2021 Dec;85(6):1592-1594. doi: 10.1016/j.jaad.2020.11.040. Epub 2020 Nov 27. PMID: 33253853.
Copy Download .nbib Format: NLM
Treatment and outcomes of pediatric patients with cancer and COVID-19 at MAHAK pediatric cancer treatment and research center, Tehran, Iran.

Seminars in oncology

Mehrvar A, Qaddoumi I, Tashvighi M, Naderi A, Mousakhani H, Alasvand R, Shekarchi B, Afsar N, Nourian M, Mehrvar N.
PMID: 34625294
Semin Oncol. 2021 Aug-Dec;48(4):295-303. doi: 10.1053/j.seminoncol.2021.09.003. Epub 2021 Sep 08.

The COVID-19 pandemic has been particularly devastating for Iran. Children with cancer are generally immunosuppressed and especially vulnerable to SARS-CoV-2 infections. We report the treatment and outcomes of pediatric oncology patients with COVID-19 at the MAHAK Pediatric Cancer Treatment...

Cite
Mehrvar A, Qaddoumi I, Tashvighi M, et al. Treatment and outcomes of pediatric patients with cancer and COVID-19 at MAHAK pediatric cancer treatment and research center, Tehran, Iran. Semin Oncol. 2021;48(4):295-303doi: 10.1053/j.seminoncol.2021.09.003.
Mehrvar, A., Qaddoumi, I., Tashvighi, M., Naderi, A., Mousakhani, H., Alasvand, R., Shekarchi, B., Afsar, N., Nourian, M., & Mehrvar, N. (2021). Treatment and outcomes of pediatric patients with cancer and COVID-19 at MAHAK pediatric cancer treatment and research center, Tehran, Iran. Seminars in oncology, 48(4), 295-303. https://doi.org/10.1053/j.seminoncol.2021.09.003
Mehrvar, Azim, et al. "Treatment and outcomes of pediatric patients with cancer and COVID-19 at MAHAK pediatric cancer treatment and research center, Tehran, Iran." Seminars in oncology vol. 48,4 (2021): 295-303. doi: https://doi.org/10.1053/j.seminoncol.2021.09.003
Mehrvar A, Qaddoumi I, Tashvighi M, Naderi A, Mousakhani H, Alasvand R, Shekarchi B, Afsar N, Nourian M, Mehrvar N. Treatment and outcomes of pediatric patients with cancer and COVID-19 at MAHAK pediatric cancer treatment and research center, Tehran, Iran. Semin Oncol. 2021 Aug-Dec;48(4):295-303. doi: 10.1053/j.seminoncol.2021.09.003. Epub 2021 Sep 08. PMID: 34625294; PMCID: PMC8424019.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 16 entries